AI Engines For more Details: Perplexity Kagi Labs You
Gastric Acid Secretion: Histamine H2 receptor agonists, when activated, stimulate the secretion of gastric acid in the stomach. This property has been utilized in the treatment of conditions like gastroesophageal reflux disease (GERD) and peptic ulcers.
Peptic Ulcers: In the past, histamine H2 receptor agonists like cimetidine, ranitidine, and famotidine were commonly used to treat peptic ulcers by reducing gastric acid secretion, thus allowing the ulcer to heal.
Gastroesophageal Reflux Disease (GERD): Histamine H2 receptor agonists have been used to alleviate symptoms of GERD, such as heartburn and acid regurgitation, by reducing the production of gastric acid.
Zollinger-Ellison Syndrome: This is a rare condition characterized by the overproduction of gastric acid. Histamine H2 receptor agonists have been used as part of the treatment regimen to reduce acid secretion and manage symptoms in individuals with this syndrome.
Adverse Effects: While histamine H2 receptor agonists have been generally well-tolerated, they can sometimes cause side effects such as headache, dizziness, diarrhea, and, rarely, more severe adverse effects like liver dysfunction or blood disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Dorea | genus | Decreases | 👪 Source Study | |
| Roseburia | genus | Decreases | 👪 Source Study | |
| Bacteroides | genus | Decreases | 👪 Source Study | |
| Lachnospira | genus | Decreases | 👪 Source Study | |
| Lacticaseibacillus | genus | Decreases | 👪 Source Study | |
| Roseburia intestinalis | species | Decreases | 📓 Source Study | |
| Lacticaseibacillus paracasei | species | Decreases | 📓 Source Study | |
| Dorea formicigenerans | species | Decreases | 📓 Source Study | |
| Lachnospira eligens | species | Decreases | 📓 Source Study | |
| Bacteroides fragilis | species | Decreases | 📓 Source Study | H02076 Bacteroides infection |
| Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases | 👶 Source Study | |
| Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases | 👶 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 0.7 | 0.9 | -0.29 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.5 | 1.9 | -0.27 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | |
| Ankylosing spondylitis | 1.2 | 0.6 | 1 |
| Anorexia Nervosa | 1.2 | -1.2 | |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 1.8 | 0.8 | 1.25 |
| Atherosclerosis | 0.4 | 1.2 | -2 |
| Atrial fibrillation | 1.3 | 0.3 | 3.33 |
| Autism | 1.5 | 2 | -0.33 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.3 | 0.5 | -0.67 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.9 | 0.9 | 0 |
| Celiac Disease | 1 | 1.2 | -0.2 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 0.3 | 1.4 | -3.67 |
| Chronic Kidney Disease | 0.9 | 0.8 | 0.13 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | -0.8 | |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 1.4 | 0.5 | 1.8 |
| Colorectal Cancer | 1 | 0.8 | 0.25 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 1 | -1 | |
| COVID-19 | 0.9 | 2.8 | -2.11 |
| Crohn's Disease | 1.5 | 2 | -0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.7 | 0.8 | -0.14 |
| Depression | 2.4 | 2.9 | -0.21 |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.9 | 0.8 | 0.13 |
| Epilepsy | 0.4 | 0.3 | 0.33 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 1.1 | 0.3 | 2.67 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 1 | 0.3 |
| gallstone disease (gsd) | 0.7 | 0.5 | 0.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 0.3 | 0.8 | -1.67 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.3 | 1.4 | -3.67 |
| Gulf War Syndrome | 0.1 | -0.1 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.5 | 0.6 | 1.5 |
| Heart Failure | 0.5 | 0.5 | 0 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.2 | 1.1 | 0.09 |
| Hypoxia | 0.9 | 0.9 | |
| IgA nephropathy (IgAN) | 0.3 | 0.7 | -1.33 |
| Inflammatory Bowel Disease | 0.4 | 1.9 | -3.75 |
| Insomnia | 0.9 | 1.1 | -0.22 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.5 | 1.1 | 0.36 |
| ischemic stroke | 0.3 | 0.8 | -1.67 |
| Liver Cirrhosis | 1.5 | 1.4 | 0.07 |
| Long COVID | 0.6 | 1.9 | -2.17 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.9 | -0.9 | |
| ME/CFS without IBS | 1.4 | -1.4 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.5 | 1.5 | 0 |
| Mood Disorders | 1.8 | 1.7 | 0.06 |
| Multiple Sclerosis | 0.6 | 1.7 | -1.83 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.1 | -1.1 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 1.1 | 0.55 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.3 | 2.4 | -0.04 |
| obsessive-compulsive disorder | 0.7 | 0.9 | -0.29 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.8 | 0.9 | -0.13 |
| Parkinson's Disease | 1 | 2.4 | -1.4 |
| Polycystic ovary syndrome | 1 | 0.8 | 0.25 |
| primary biliary cholangitis | 0.6 | 0.6 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.7 | 0.8 | -0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 1.5 | 0.53 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.6 | 1.1 | -0.83 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.9 | -0.9 | |
| Sleep Apnea | 0.9 | 0.8 | 0.13 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1.4 | 0.8 | 0.75 |
| Systemic Lupus Erythematosus | 0.4 | 0.8 | -1 |
| Tic Disorder | 0.6 | -0.6 | |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 1 | 1.1 | -0.1 |
| Type 2 Diabetes | 1.5 | 1.6 | -0.07 |
| Ulcerative colitis | 1.3 | 1 | 0.3 |
| Unhealthy Ageing | 1 | 0.5 | 1 |
| Vitiligo | 0.7 | 0.7 |
